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a,-Adrenergic receptor-mediated inhibition of adenylate cyclase requires the guanine nucleotide-binding 
protein, N,. This protein may also be required for stabilization of high-affinity a,-adrenergic agonist binding. 
Human platelet membranes treated under alkaline conditions (PH 11.5) exhibited a selective loss of high- 
affinity agonist binding as measured byp-[3H]aminoclonidine and [3H]UK 14,304. Binding of the antagonist 
[3H]yohimbine was largely unaffected with retention of >60% of control binding sites. N,, determined by 
pertussis toxin-catalyzed [32P]ADP-ribosylation of cholate extracts from alkaline-treated membranes, was 
also markedly reduced. The parallel loss of ax-agonist binding and N, provides additional evidence that N, 
is required for a,-adrenergic agonist binding. 
a,-Adrenergic receptor Agonist binding Nucleotide-binding protein Alkaline treatment 
1. INTRODUCTION 
Adrenergic regulation of adenylate cyclase can 
be either stimulatory or inhibitory. Agonist- 
induced attenuation of adenylate cyclase activity 
has been demonstrated in several systems including 
those containing az-adrenergic [11, muscarinic [2] 
and opiate receptors [3]. This effect requires a 
guanyl nucleotide regulatory protein, pi [4]. 
Agonist binding to inhibitory receptors may also 
involve an interaction with Ni, but this is less well 
characterized. GTP analogs decrease the affinity 
of crz-adrenergic agonist binding with no decrease 
in antagonist binding [5,6] or even an increase [7]. 
Abbreviations: IAP, islet-activating protein (pertussis 
toxin); Ni, inhibitory guanine nucleotide-binding pro- 
tein; N,, stimulatory guanine nucleotide-binding pro- 
tein; PAC, p-aminoclonidine; P/Y, ratio of specifically 
bound 3 nM [3H]PAC/10 nM [jH]yohimbine; TM, buf- 
fer containing 50 mM Tris-Cl, pH 7.6, 10 mM MgC12; 
TME, TM buffer supplemented with 1 mM EGTA; UK 
14,304, 5-bromo-6-N-[2-(4,5-dihydroimidazolyl)]quin- 
oxaline 
A similar reduction of agonist binding has also 
been demonstrated for membranes from cells 
treated with pertussis toxin [8-lo]. Because of 
these observations, it has been hypothesized that 
inhibitory agonist binding to human platelet 
cuz-receptors equires Ni. 
Citri and Schramm reported a selective inactiva- 
tion of the stimulatory guanine nucleotide regula- 
tory protein, N,, and the catalytic subunit of 
adenylate cyclase, C, after treatment of turkey 
erythrocyte membranes with alkaline buffer [ll, 
121. Here, we report a selective abolition of high- 
affinity az-agonist binding without significant in- 
activation of antagonist binding following pre- 
treatment of human platelet membranes under 
alkaline conditions. This effect is correlated with a 
parallel decrease in pertussis toxin-catalyzed 
[32P]ADP-ribosylation of Ni. These observations 
provide additional evidence that high-affinity 
agonist binding to platelet a*-adrenergic receptors 
requires a functional Ni protein and provides a new 
tool for studying this interaction. A preliminary 
report of this work has been presented in abstract 
form [13]. 
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2. MATERIALS AND METHODS 
2.1. Purification of platelet membranes 
Purified human platelet membranes were pre- 
pared by the method of Neubig and Szamraj [15] 
and stored at -70°C for up to 6 weeks prior to 
use. 
2.2. Alkaline treatment 
Platelet membranes were thawed, homogenized 
with 5 strokes in a Potter-Elvehjem homogenizer, 
and diluted 20-fold with 50 mm sodium phosphate 
(pH 7.6-12.0). After incubation on ice for 1 h, 
membranes were collected by centrifugation at 
145 000 x g for 30 min and resuspended in buffer A 
(50 mM Tris-Cl, 10 mM MgC12, 1 mM EGTA, pH 
7.6) for binding assays and pertussis toxin label- 
ling. 
2.3. Binding assays and pertussis toxin labelling 
Reagents and methods for measurement of [3H]- 
yohimbine, p-[3H]aminoclonidine and [3H]UK 
14,304 binding, cholate extractions and pertussis 
labelling of Ni were as described [141. Binding data 
were determined in triplicate and are presented as 
mean +-SD. Curvilinear Scatchard plots were 
analyzed using the SCAFIT computer program 
[161. 
3. RESULTS 
Incubation of purified platelet membranes at a 
pH up to 11 .O for 1 h did not affect binding of 10 
nM [3H]yohimbine; however, at pH 11.5-12, there 
was a partial reduction in binding (fig.1). High- 
affinity agonist binding as measured by 3 nM 
[‘H]PAC was also unaffected to pH 11 .O, but was 
completely lost at pH 11.5 or greater (fig. 1). This 
effect of pH was complete in less than 30 min (not 
shown); consequently, 1 h was used as a standard 
incubation condition. 
Equilibrium binding curves for [3H]PAC and 
r3H]yohimbine were performed with membranes 
pretreated in 50 mM phosphate buffer, pH 7.6 
(control) and pH 11.5 (pH 11.5 membranes). 
There was no significant change in & and only a 
slight reduction in Bmax for yohimbine binding to 
pH 11.5 membranes (fig.2A). Analysis using 
SCAFIT showed the best fit to a one-site model 
with a Kd and Bmax for control membranes of 
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Fig.1. Dependence of binding to [3H]PAC and 13Hl 
yohimbine on pretreatment pH. Equilibrium binding of 
3 nM 13H]PAC (m) and 10 nM [‘Hlyohimbine (0) was 
measured for membranes pretreated with 50 mM sodium 
phosphate at the indicated pH and returned to pH 7.6 as 
described in section 2. Data are presented as mean f SD 
of triplicate determinations of specific binding per mg 
measured protein. The experiment shown is represen- 
tative of 4 such experiments with similar results. 
3.9kO.5 nM and 4OOk 115 fmol/mg (n = 4). 
Because of the removal of approx. 50% of the pro- 
tein, the actual recovery of yohimbine binding sites 
was 50-60% following alkaline pretreatment. 
The PAC binding curve for control membranes 
exhibits a nonlinear Scatchard plot (fig.ZB). A 
2-site fit was appropriate with K&=0.7 nM, 
Kd2= 8 nM, B1 =76, Bz= 198 fmob’mg [14]. In 
contrast, pH 11.5-treated membranes are charac- 
terized by only a very small amount of [3H]PAC 
binding (fig.2B). The high-affinity [3H]PAC 
binding seen for control membranes is not present 
with the pH 11.5 membranes. Binding is best fitted 
by a l-site model with,&, 3.4 +O.l nM and B,,,, 
100 * 20 fmol/mg (n = 3). 
To assess the effect of alkaline treatment on the 
inhibitory guanine nucleotide-binding protein, per- 
tussis toxin-catalyzed [32P]ADP-ribosylation of 
the a-subunit (M, 41000) of Ni was used to quan- 
titate amounts of that protein in cholate extracts 
from membranes pretreated at pH ranging from 
7.6 to 12.0 (fig.3). There is a gradual decrease of 
approx. 50% in the amount of labelling of the Ni 
a-subunit from pH 7.6 to 11 .O. At pH 11.5 a near- 
ly complete abolition of labelling occurs. This 
sharp decrease parallels the decrease observed in 
high-affinity agonist binding. In some prepara- 
tions of pH-pretreated membranes, we observed 
an increase in labelling at pH 10.-O, however, in all 
cases, there was a decrease for pH 11 .O or greater. 
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Fig.2. Scatchard transformation of the binding of (A) 
[3H]yohimbine and (B) [3H]PAC to control (0) and pH 
11 S-pretreated (w) membranes. Binding was measured 
as described in section 2. Data are expressed as fmol/mg 
measured protein and are from a single experiment 
representative of (A) 6 and (B) 3 experiments with 
similar results. 
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Fig.3. [32P]NAD labelling of Nr in cholate extracts 
prepared from membranes pre-treated at various pH 
values. IAP-catalyzed Ni labelling by [32P]NAD was per- 
formed as in section 2 followed by SDS-polyacrylamide 
gel electrophoresis. The dried gel was exposed to X-ray 
film for 6 h and a single labelled band was observed with 
M,= 40 700 [ 131. No radioactivity was observed in the 
lane without added IAP. Three other experiments were 
performed with similar results. 
A comparison of the amount of 32P incor- 
porated into the 41 kDa protein with a measure of 
high-affinity agonist binding (P/Y, see figure 
legend) is plotted as a function of pH (fig.4). There 
is a marked decrease in high-affinity binding with 
a concomitant abolition of Ni labelling at pH 11.5 
or greater. Interestingly, inactivation of - 50% of 
Ni (pH 10.5) occurs without any significant effect 
on agonist binding. [Note: Recent experiments 
with pertussis toxin treatment of platelet mem- 
Pretreatment pH 
Fig.4. Dependence of P/Y and [32P]NAD incorporation 
on alkaline pH pre-treatment. Data from fig. 1 were used 
to calculate P/Y, the ratio of 3 nM [‘H]PAC/lO nM 
[3H]yohimbine specifically bound. This index of high- 
affinity agonist binding is plotted as a function of pre- 
treatment pH (w). Errors of triplicates are ~20%. N, 
labelling of 2% cholate extracts (A) was quantitated by 
excising and counting the labelled bands from the gel in 
fig.4. Error bars depict the ranges of duplicate lanes. 
Background counts from the lane containing no per- 
tussis toxin (150 cpm) were subtracted from all points. 
Data are presented in pmol NAD per mg starting protein 
(5 ,ug per point). 
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branes show that modification of 50-70% of the 
Ni is without effect on [3H]PAC binding. Com- 
plete modification of Ni in membranes has not yet 
been achieved (Kim and Neubig, unpublished).] 
The amount of pertussis toxin substrate (Ni) in 
controls (pH 7.6) was 28 (range 9-47) pmol 
[32P]NAD incorporated/mg protein (n = 4) com- 
pared with that for pH 11.5-treated membranes, 
which was 3.0 (range l-6) pmol/mg protein 
(n =3). The binding of the full az-adrenergic 
agonist [3H]UK 14,304 is also reduced by alkaline 
treatment. The ratio of specific binding of 2 nM 
[3H]UK 14,304 to that of 10 nM [3H]yohimbine 
was reduced from the control value of pretreated 
membranes 0.39 + 0.04, to 0.05 + 0.01 in pH 1 I .5 
(n=3). 
4. DISCUSSION 
We show here that treatment of purified platelet 
membranes under extreme alkaline conditions (pH 
11.5) results in the selective inactivation of binding 
of. the partial cuz-agonist, [3H]PAC, and full 
a2-agonist [3H]UK, 14,304 but not that of the an- 
tagonist, [3H]yohimbine. This is the first report of 
the effect of alkaline treatment on adrenergic 
agonist binding. Because the results obtained 
following pH 11.5 treatment resembled those seen 
for PAC binding in the presence of lo-’ M 
GppNHp [14], we hypothesized that the selective 
reduction of agonist binding might be due to loss 
of Ni. Indeed, Ni measured by pertussis toxin 
catalyzed [32P]ADP-ribosylation is inactivated by 
alkaline treatment (fig.4). These observations 
parallel those of Citri and Schramm [ll, 121 on 
alkaline treatment of ,&adrenergic receptors where 
N, is inactivated but antagonist binding is 
preserved. 
Selective reduction of a2-agonist binding has 
also been reported for the reversible reagents 
sodium [ 171 and GppNHp [14] and irreversible 
reagents N-ethylmaleimide [ 18,191, chymotrypsin 
[20], heat [19] and pertussis toxin [g-lo]. Only for 
the latter is the mechanism known to involve ef- 
fects on the inhibitory guanine nucleotide-binding 
protein, Ni. The parallel loss of pertussis toxin 
substrate and a2-agonist binding between pH 11 .O 
and 11.5 suggests that inactivation of Ni results in 
the selective loss of high-affinity agonist binding. 
Final proof of this mechanism would require 
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reconstitution of high-affinity agonist binding with 
purified Ni. This type of experiment has recently 
been performed using solubilized muscarinic 
receptors [21]. 
Although the complete inactivation of Ni paral- 
lels the loss of [3H]PAC binding, in each experi- 
ment there was some decrease in pertussis toxin 
substrate at pH 10.5-11 without loss of agonist 
binding. It is possible that alkaline treatment af- 
fects the activity of Ni as a pertussis toxin substrate 
(e.g. by dissociating the subunits) without affec- 
ting its ability to couple to receptors. Another like- 
ly explanation can be found in the fact that there 
is a 25-lOO-fold excess of Ni protein over &2-recep- 
tors in platelet membranes [14]. Consequently, in- 
activation of 50-80% of the Ni would still leave 
more than enough to couple to cyz-adrenergic 
receptors’ (see Note, p. 323). 
Recently, Childers and co-workers [22,23] 
studied the effects of acid (pH 4.5) treatment of 
brain membranes on opiate receptors. Control 
agonist binding was apparently not changed but 
the sensitivity to guanine nucleotides was in- 
creased. Also, opiate receptor-mediated inhibition 
of adenylate cyclase was increased. The relation of 
these observations to our present findings is not 
clear. Effects of alkaline treatment on receptor- 
mediated inhibition of adenylate cyclase in our 
system cannot be determined because catalytic ac- 
tivity is completely inactivated at pH 11 (not 
shown). 
Our data provide additional evidence for the 
role of the guanine nucleotide-binding protein, Ni, 
in promoting high-affinity az-agonist (and partial 
agonist) binding. Alkaline treatment should prove 
a useful tool in studying receptor-Ni interactions. 
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